LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 13 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 3. - Dataset (ID:20250)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
SK-BR-3 | CP724714 | 3.33 | uM | LJP5 | 72 | hr | 1401 | 1856 | 4245 | 0.4371 | 0.1900 |
SK-BR-3 | CP724714 | 1.11 | uM | LJP5 | 72 | hr | 1401 | 2141 | 4245 | 0.5061 | 0.3052 |
SK-BR-3 | CP724714 | 0.37 | uM | LJP5 | 72 | hr | 1401 | 2441 | 4245 | 0.5768 | 0.4166 |
SK-BR-3 | CP724714 | 0.12 | uM | LJP5 | 72 | hr | 1401 | 2814 | 4245 | 0.6638 | 0.5469 |
SK-BR-3 | CP724714 | 0.04 | uM | LJP5 | 72 | hr | 1401 | 3625 | 4245 | 0.8590 | 0.8209 |
SK-BR-3 | CP466722 | 10 | uM | LJP5 | 72 | hr | 1401 | 2026 | 4245 | 0.4771 | 0.2567 |
SK-BR-3 | CP466722 | 3.33 | uM | LJP5 | 72 | hr | 1401 | 3557 | 4245 | 0.8426 | 0.7983 |
SK-BR-3 | CP466722 | 1.11 | uM | LJP5 | 72 | hr | 1401 | 4261 | 4245 | 1.0100 | 1.0149 |
SK-BR-3 | CP466722 | 0.37 | uM | LJP5 | 72 | hr | 1401 | 4613 | 4245 | 1.0928 | 1.1181 |
SK-BR-3 | CP466722 | 0.12 | uM | LJP5 | 72 | hr | 1401 | 4299 | 4245 | 1.0206 | 1.0288 |
SK-BR-3 | CP466722 | 0.04 | uM | LJP5 | 72 | hr | 1401 | 4863 | 4245 | 1.1519 | 1.1903 |
SK-BR-3 | Sorafenib | 10 | uM | LJP6 | 72 | hr | 1401 | 2693 | 4168 | 0.6469 | 0.5157 |
SK-BR-3 | Sorafenib | 3.33 | uM | LJP6 | 72 | hr | 1401 | 4352 | 4168 | 1.0443 | 1.0563 |
SK-BR-3 | Sorafenib | 1.11 | uM | LJP6 | 72 | hr | 1401 | 4107 | 4168 | 0.9848 | 0.9801 |
SK-BR-3 | Sorafenib | 0.37 | uM | LJP6 | 72 | hr | 1401 | 4190 | 4168 | 1.0057 | 1.0077 |
SK-BR-3 | Sorafenib | 0.12 | uM | LJP6 | 72 | hr | 1401 | 4043 | 4168 | 0.9705 | 0.9625 |
SK-BR-3 | Sorafenib | 0.04 | uM | LJP6 | 72 | hr | 1401 | 3852 | 4168 | 0.9237 | 0.9010 |
SK-BR-3 | AZD8055 | 10 | uM | LJP6 | 72 | hr | 1401 | 443 | 4168 | 0.1063 | -0.5192 |
SK-BR-3 | AZD8055 | 3.33 | uM | LJP6 | 72 | hr | 1401 | 1289 | 4168 | 0.3097 | -0.0518 |
SK-BR-3 | AZD8055 | 1.11 | uM | LJP6 | 72 | hr | 1401 | 1306 | 4168 | 0.3138 | -0.0436 |
SK-BR-3 | AZD8055 | 0.37 | uM | LJP6 | 72 | hr | 1401 | 1361 | 4168 | 0.3270 | -0.0182 |
SK-BR-3 | AZD8055 | 0.12 | uM | LJP6 | 72 | hr | 1401 | 1438 | 4168 | 0.3455 | 0.0170 |
SK-BR-3 | AZD8055 | 0.04 | uM | LJP6 | 72 | hr | 1401 | 1460 | 4168 | 0.3504 | 0.0264 |
SK-BR-3 | AZD7762 | 10 | uM | LJP6 | 72 | hr | 1401 | 856 | 4168 | 0.2056 | -0.2694 |
SK-BR-3 | AZD7762 | 3.33 | uM | LJP6 | 72 | hr | 1401 | 1020 | 4168 | 0.2452 | -0.1849 |